Bristol-Myers Squibb Co (LTS:0R1F)
$ 59.4 -0.61 (-1.02%) Market Cap: 119.70 Bil Enterprise Value: 163.01 Bil PE Ratio: 0 PB Ratio: 6.98 GF Score: 82/100

Bristol-Myers Squibb Co at UBS Global Healthcare Conference Transcript

May 21, 2019 / 06:30PM GMT
Release Date Price: $46.31 (-0.65%)
Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Good afternoon. My name is Navin Jacob. I'm the senior analyst covering pharmaceuticals and midcap biotech, UBS. Our next session is with Bristol-Myers Squibb. I'm happy to have with us Chairman and CEO, Giovanni Caforio. Giovanni, thank you for joining us today.

Giovanni Caforio
Bristol-Myers Squibb Company - Chairman of the Board & CEO

Thank you, Navin. Thank you. Good afternoon, everyone. Thanks for having me.

Questions & Answers

Navin Cyriac Jacob
UBS Investment Bank, Research Division - Equity Research Analyst of Specialty Pharmaceuticals and Large Cap Pharmaceutic

Giovanni, you're -- you have -- you're wearing many hats. You're Chairman and CEO of Bristol-Myers, going through a big deal. You're also a Chairman Elect of the Pharma Trade Group. Wondering given all the discussion around pharma pricing, IPI is coming out maybe over the next few weeks. We had

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot